Bladder cancer, Kidney cancer
Open
Phase 3
This trial is looking at the combination of a treatment called V940 and pembrolizumab for urothelial cancer. It is comparing this to having pembrolizumab on its own. It is for people whose cancer:
had grown into the muscle layer of the bladder or upper urinary tract and they have had surgery with the aim to cure
has a higher chance of coming back
Recruitment start: 5 July 2024
Recruitment end: 8 September 2025
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Tom Powles
Merck Sharp & Dohme LLC
Last reviewed: 4 March 2025
CRUK internal database number: 19947